Claims
- 1. A lipophilic pharmaceutical formulation for oral administration consisting essentially of a digestible medium chain triglyceride and probucol, said probucol having a concentration greater than about 5% by weight, and said probucol being completely dissolved in said digestible medium chain triglyceride.
- 2. The lipophilic pharmaceutical formulation recited in claim 1 wherein said formulation includes ethanol.
- 3. The lipophilic pharmaceutical formulation recited in claim 2 wherein said ethanol is present in a concentration of less than about 10% by weight.
- 4. The lipophilic pharmaceutical formulation recited in claim 3 wherein said probucol is present in an amount of between about 5 and 15% by weight and said medium chain triglyceride is present in an amount of greater than about 80% by weight of said solution.
- 5. The lipophilic pharmaceutical formulation recited in claim 3 wherein said ethanol is present in a concentration of about 5% by weight.
- 6. The lipophilic pharmaceutical formulation recited in claim 1 wherein said probucol is present in an amount of between about 5 and 15% by weight and said medium chain triglyceride is present in an amount of greater than about 80% by weight of said solution.
- 7. The lipophilic pharmaceutical formulation recited in claim 1 wherein said medium chain triglyceride has fatty acid chains each with 6 to 12 carbon atoms.
- 8. The lipophilic pharmaceutical formulation recited in claim 1 wherein said probucol is present in an amount of between about 8% and 13% by weight.
- 9. A method for increasing probucol absorption by an organism, said method comprising orally administering to the organism a solution consisting essentially of greater than about 5% by weight probucol dissolved in a digestible medium chain triglyceride.
- 10. The method recited in claim 9 wherein said solution includes ethanol.
- 11. The method recited in claim 10 wherein said ethanol is present in a concentration of less than about 10% by weight.
- 12. The method recited in claim 11 wherein said probucol is present in an amount of between about 5 and 15% by weight and said medium chain triglyceride is present in an amount of greater than about 80% by weight of said solution.
- 13. The method recited in claim 11 wherein said ethanol is present in a concentration of about 5% by weight.
- 14. The method recited in claim 9 wherein said probucol is present in an amount of between about 5 and 15% by weight and said medium chain triglyceride is present in an amount of greater than about 80% by weight of said solution.
- 15. The method recited in claim 9 wherein said medium chain triglyceride has side chains with 6 to 12 carbon atoms.
- 16. The method recited in claim 9 wherein said organism is a human.
- 17. The method recited in claim 16 wherein probucol is administered in single doses of between about 5 and about 40 mg probucol/kg body weight.
- 18. The method recited in claim 16 wherein probucol is admistered in a dose of between about 100 and 1000 mg/day.
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a Continuation of application Ser. No. 08/053,898, filed Apr. 27, 1993, now abandoned, which is a Continuation-In-Part of U.S. Ser. No. 07/874,774, filed Apr. 27, 1992 (Sanchez and Hendler inventors), now abandoned, which is incorporated herein by reference for all purposes.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4985465 |
Hendler |
Jan 1991 |
|
Non-Patent Literature Citations (2)
Entry |
Hegg et al., J. of Pharm. Sci., 73(12), pp. 1758-1763 (1984). |
Palin et al., J. Pharmacy & Pharacology, 35, p. 85p (1983). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
53898 |
Apr 1993 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
874774 |
Apr 1992 |
|